Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS)

NCT01692262 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01692262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01692262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS)
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2012
Completion date
June 30, 2014
Enrollment
59 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy,, metastatic castrate-resistant prostate cancer (mcrpc),, pharmacodynamics,, pharmacokinetics,, safety and tolerability,, tumour response.